Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Expression of Cd133 Cancer Stem Cell Marker in Melanoma: A Systematic Review and Meta-Analysis Publisher Pubmed



Madjd Z1, 2 ; Erfani E1 ; Gheytanchi E1 ; Moradilakeh M3, 4 ; Shariftabrizi A5 ; Asadilari M1, 6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Community Medicine, Iran University of Medical Sciences and Health Services, Tehran, Iran
  4. 4. Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, United States
  5. 5. Department of Nuclear Medicine and Molecular Imaging, State University of New York at Buffalo, Buffalo, NY, United States
  6. 6. Department of Epidemiology, Iran University of Medical Sciences, Tehran, Iran

Source: International Journal of Biological Markers Published:2016


Abstract

Background: CD133-positive melanoma cells are thought to be melanoma-initiating cells with cancer stem cell (CSC) characteristics. Some researchers have reported that CD133-negative subsets can also initiate tumors, so the clinical significance of a CD133-positive subpopulation of cells in melanoma remains controversial. This systematic review was designed to assess the value of CD133 as a CSC marker in melanomas. A meta-analysis was also performed to cumulatively analyze the data on CD133 expression levels in the selected studies. Materials and method: Eligible studies were identified via an electronic search through various databases including PubMed, MEDLINE, Ovid MEDLINE, and Web of Science (from May 2005 through September 2014) using the following keywords: “CD133 or prominin-1”, “cancer stem cells”, and “melanoma”. Only articles in which CD133 antigen was detected by immunohistochemistry (IHC) were included. A meta-analysis was performed to identify any association between CD133 expression and clinical outcomes. Results: Two hundred and ninety-nine melanoma cases from 5 studies were evaluated for expression levels of CD133 using IHC. Large heterogeneity was observed among the results (p<0.001, I2 = 94%). Approximately 47.9% (95% CI 23.7%-72.1%) of the studied melanoma cases had high CD133 expression. The I2 value and Q-test p value for heterogeneity were 89.0% and <0.001, respectively, and the pooled estimate of CD133 expression was 61.7% (95% CI 25.1%-98.4%). Conclusions: Our findings suggest that CD133 is not yet proven to be an appropriate biomarker in identifying CSCs of melanoma. Thus, detection of CD133 in combination with other putative CSC markers may be more valuable for clinical application. © 2016 Wichtig Publishing.
Related Docs
View other Related Docs
1. Cancer Stem Cell Research in Iran: Potentials and Challenges, Future Oncology (2017)
2. Comparative Gene-Expression Profiling of Cd133+ and Cd133- D10 Melanoma Cells, Future Oncology (2015)
3. Glance Into Cancer Stem Cells, Journal of Kerman University of Medical Sciences (2016)
4. Co-Expression of Putative Cancer Stem Cell Markers Cd44 and Cd133 in Prostate Carcinomas, Pathology and Oncology Research (2017)
5. Mechanisms of Tumor Cell Resistance to the Current Targeted-Therapy Agents, Tumor Biology (2016)
6. Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools, ACS Pharmacology and Translational Science (2023)
7. Application of Nanotechnology in Targeting of Cancer Stem Cells: A Review, International Journal of Stem Cells (2019)
8. Deciphering Biological Characteristics of Tumorigenic Subpopulations in Human Colorectal Cancer Reveals Cellular Plasticity, Journal of Research in Medical Sciences (2016)
Experts (# of related papers)
View all Related Experts
Hamid Reza Mirzaei (2)
Arezoo Rasti (2)
Other Related Docs
9. Differential Expression of Cancer Stem Cell Markers Aldh1 and Cd133 in Various Lung Cancer Subtypes, Cancer Investigation (2015)
10. Current Approaches in Identification and Isolation of Cancer Stem Cells, Journal of Cellular Physiology (2019)
11. Local Immunotherapy of Glioblastoma: A Comprehensive Review of the Concept, Journal of Neuroimmunology (2023)
12. Nano-Delivery System Targeting to Cancer Stem Cell Cluster of Differentiation Biomarkers, Journal of Controlled Release (2017)
13. Epigenetic of Retinoic Acid Receptor ß2 Gene in Breast Cancer, Epigenetics Territory and Cancer (2015)
14. High Gd2 Expression Defines Breast Cancer Cells With Enhanced Invasiveness, Experimental and Molecular Pathology (2019)
15. Clinicopathological Significance of Tumor Stem Cell Markers Aldh1 and Cd133 in Colorectal Carcinoma, Iranian Journal of Pathology (2021)
16. Cytoplasmic Expression of Cd133 Stemness Marker Is Associated With Tumor Aggressiveness in Clear Cell Renal Cell Carcinoma, Experimental and Molecular Pathology (2017)
17. Dendritic Cell Based Immunotherapy Using Tumor Stem Cells Mediates Potent Antitumor Immune Responses, Cancer Letters (2016)
18. Cancer Stem Cells and Oral Cancer: Insights Into Molecular Mechanisms and Therapeutic Approaches, Cancer Cell International (2020)
19. Cancer Stem-Like Cell Behavior in Anaplastic Thyroid Cancer: A Challenging Dilemma, Life Sciences (2016)
20. Verification of Aldh Activity As a Biomarker in Colon Cancer Stem Cells-Derived Ht-29 Cell Line, International Journal of Cancer Management (2015)
21. Expression Patterns for Tets, Lgr5 and Bmi1 in Cancer Stem-Like Cells Isolated From Human Colon Cancer, Avicenna Journal of Medical Biotechnology (2019)
22. Immunopathology and Immunotherapy of Myeloid Leukemia, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
23. Increased Expression of Cd44 Is Associated With More Aggressive Behavior in Clear Cell Renal Cell Carcinoma, Biomarkers in Medicine (2018)
24. Cancer Stem Cell’S Potential Clinical Implications, International Journal of Cancer Management (2017)
25. Evaluation of Genistein Effect on Invasion of Breast Cancer Stem Cell-Like Cells, Acta Medica Iranica (2018)
26. Morphological and Molecular Characteristics of Spheroid Formation in Ht-29 and Caco-2 Colorectal Cancer Cell Lines, Cancer Cell International (2021)
27. Functionalised Nanomaterials for Eradication of Cscs, a Promising Approach for Overcoming Tumour Heterogeneity, Journal of Drug Targeting (2018)
28. Anticancer Properties of a New Platinum (Iv) Agent on Ht1080 Cancer Stem-Like Cells: An in Vitro Study, Acta Medica Iranica (2022)
29. Competing Endogenous Rnas Regulatory Crosstalk Networks: The Messages From the Rna World to Signaling Pathways Directing Cancer Stem Cell Development, Heliyon (2024)
30. Cancer Stem Cells, Stem Cells in Urology (2020)
31. Cancer Stem Cell-Targeted Chimeric Antigen Receptor (Car)-T Cell Therapy: Challenges and Prospects, Acta Pharmaceutica Sinica B (2021)
32. Prognostic Significance of Cancer Stem Cell Markers in Patients With Salivary Gland Carcinomas, Applied Immunohistochemistry and Molecular Morphology (2022)
33. The Role of Hypoxia-Inducible Factors in Breast Cancer Stem Cell Specification, Pathology Research and Practice (2023)
34. Evaluation of Circulating Cellular Dclk1 Protein, As the Most Promising Colorectal Cancer Stem Cell Marker, Using Immunoassay Based Methods, Cancer Biomarkers (2016)
35. Breast Cancer: Biology, Biomarkers, and Treatments, International Immunopharmacology (2020)